MAP2K7 and neuroblastoma: Given the potential difference in therapeutic window with MEK inhibitor and the importance of NF1 levels for successful RA therapy (Holzel et al., 2010), we believe that SHP2 inhibition either by itself or incorporated into maintenance therapy for high-risk NB warrants further investigation.